NO20074593L - Tartrat- og malatsalter av trans-1-(6-klor-3-fenylindan-1-yl)-3,3-dimetylpiperazin - Google Patents

Tartrat- og malatsalter av trans-1-(6-klor-3-fenylindan-1-yl)-3,3-dimetylpiperazin

Info

Publication number
NO20074593L
NO20074593L NO20074593A NO20074593A NO20074593L NO 20074593 L NO20074593 L NO 20074593L NO 20074593 A NO20074593 A NO 20074593A NO 20074593 A NO20074593 A NO 20074593A NO 20074593 L NO20074593 L NO 20074593L
Authority
NO
Norway
Prior art keywords
phenylindan
dimethylpiperazine
tartrate
trans
chloro
Prior art date
Application number
NO20074593A
Other languages
English (en)
Inventor
Ole Nielsen
Benny Bang-Andersen
Heidi Lopez De Diego
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of NO20074593L publication Critical patent/NO20074593L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/06—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals
    • C07D295/073—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals with the ring nitrogen atoms and the substituents separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Et tartrat- og malatsalt av trans-1-(6-klor-3-fenylindan-1-yl)-3,3-dimetylpiperazin, spesielt for medisinsk anvendelse, farmasøytiske formuleringer derav, inklusive for behandling av schizofreni eller andre sykdommer som involverer psykotiske symptomer
NO20074593A 2005-02-16 2007-09-11 Tartrat- og malatsalter av trans-1-(6-klor-3-fenylindan-1-yl)-3,3-dimetylpiperazin NO20074593L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US65341805P 2005-02-16 2005-02-16
DKPA200500238 2005-02-16
PCT/DK2006/000087 WO2006086985A1 (en) 2005-02-16 2006-02-14 Tartrate and malate salts of trans-1-((1r,3s)-6-chloro-3-phenylindan-1-yl)-3,3-dimethylpiperazine

Publications (1)

Publication Number Publication Date
NO20074593L true NO20074593L (no) 2007-09-11

Family

ID=36143437

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20074593A NO20074593L (no) 2005-02-16 2007-09-11 Tartrat- og malatsalter av trans-1-(6-klor-3-fenylindan-1-yl)-3,3-dimetylpiperazin

Country Status (8)

Country Link
US (1) US20080269248A1 (no)
EP (1) EP1853575A1 (no)
JP (1) JP2008530039A (no)
AU (1) AU2006215956A1 (no)
CA (1) CA2597620A1 (no)
MX (1) MX2007009816A (no)
NO (1) NO20074593L (no)
WO (1) WO2006086985A1 (no)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010037398A1 (en) * 2008-10-03 2010-04-08 H. Lundbeck A/S Oral formulation
BRPI0413595B8 (pt) 2003-08-18 2021-05-25 H Lundbeck As sal de malonato, composição farmacêutica, uso de um sal de malonato, e, método de fabricação de um composto
TWI376373B (en) 2005-02-16 2012-11-11 Lundbeck & Co As H Crystalline base of a pharmaceutical compound
TWI453198B (zh) 2005-02-16 2014-09-21 Lundbeck & Co As H 製造反式-1-((1r,3s)-6-氯基-3-苯基茚滿-1-基) -3 , 3 -二甲基六氫吡與其鹽類之方法及製造4-((1r , 3s）-6 -氯基-3-苯基茚滿-1-基 )-1,2,2-三甲基六氫吡與其鹽類之方法
BRPI0912223A2 (pt) * 2008-05-07 2015-10-06 Lundbeck & Co As H métodos para melhorar funcionamento cognitivo e para tratar uma doença, composto, uso do mesmo, e, composição farmacêutica.
TW201102370A (en) * 2009-07-07 2011-01-16 Lundbeck & Co As H Manufacture of 4-((1R,3S)-6-chloro-3-phenyl-indan-1-yl)-1,2,2-trimethyl-piperazine and 1-((1R,3S)-6-chloro-3-phenyl-indan-1-yl)-3,3-dimethyl piperazine
JP2014501771A (ja) 2011-01-07 2014-01-23 ハー・ルンドベック・アクチエゼルスカベット ４−（（１ｒ，３ｓ）−６−クロロ−３−フェニル−インダン−１−イル）−１，２，２−トリメチル−ピペラジンと１−（（１ｒ，３ｓ）−６−クロロ−３−フェニル−インダン，１−イル）−３，３−ジメチル−ピペラジンとを分割するための方法
JP5668177B2 (ja) 2011-06-20 2015-02-12 ハー・ルンドベック・アクチエゼルスカベット 統合失調症の治療のための重水素化１−ピペラジノ−３−フェニルインダン
CN112930341A (zh) 2018-10-29 2021-06-08 H.隆德贝克有限公司 无定形的具有式(i)的化合物和无定形的具有式(i)的化合物的盐
WO2020114853A1 (en) 2018-12-03 2020-06-11 H. Lundbeck A/S Prodrugs of 4-((1r,3s)-6-chloro-3-phenyl-2,3-dihydro-1h-inden-1-yl)-1,2,2-trimethylpiperazine and 4-((1/r,3s)-6-chloro-3-(phenyl-d5)-2,3-dihydro-1h-inden-1-yl)-2,2-dimethy-1-(methyl-d3)piperazine

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ196284A (en) * 1980-02-29 1983-12-16 Kefalas As 1-piperazino-3-phenylindane derivatives:pharmaceutical compositions
DK55192D0 (da) * 1992-04-28 1992-04-28 Lundbeck & Co As H 1-piperazino-1,2-dihydroindenderivater
US6455736B1 (en) * 1994-12-16 2002-09-24 Uop Llc Process for preparation of pharmaceutically desired sertraline and sertraline analogs
US6410794B1 (en) * 1994-12-16 2002-06-25 Uop Llc Process for preparation of pharmaceutically desired chiral tetralone from tetralones
DE69913332T2 (de) * 1998-05-01 2004-05-27 Pfizer Products Inc., Groton Verfahren zur herstellung von enantiomeren reinem oder optisch angereicherter sertraline-tetralon durch kontinuierliche chromatographie
IN187170B (no) * 2000-01-04 2002-02-23 Sun Pharmaceutical Ind Ltd
BRPI0413595B8 (pt) * 2003-08-18 2021-05-25 H Lundbeck As sal de malonato, composição farmacêutica, uso de um sal de malonato, e, método de fabricação de um composto

Also Published As

Publication number Publication date
AU2006215956A1 (en) 2006-08-24
CA2597620A1 (en) 2006-08-24
EP1853575A1 (en) 2007-11-14
US20080269248A1 (en) 2008-10-30
WO2006086985A1 (en) 2006-08-24
MX2007009816A (es) 2007-09-07
JP2008530039A (ja) 2008-08-07

Similar Documents

Publication Publication Date Title
NO20074593L (no) Tartrat- og malatsalter av trans-1-(6-klor-3-fenylindan-1-yl)-3,3-dimetylpiperazin
NO20061153L (no) Trans-1-(6-klor-3-fenylindan-1-yl)-3,3-dimetylpiperazin
CY1120741T1 (el) Θεραπεια οζωδους σκληρυνσης
UA107115C2 (uk) Тіоацетатні похідіні піридину, композиція на їх основі та їх застосування
BRPI0510515A (pt) compostos de morfolina
EA200701175A1 (ru) Лекарственные средства, предназначенные для лечения или предупреждения фиброзных заболеваний
EA200901373A1 (ru) Аминогетероциклические соединения
NO20056130L (no) Nye substituerte 3-svovelindoler
BRPI0513379A (pt) derivados de sulfonamida
NO20083324L (no) Multisykliske aminosyrederivater og anvendelse derav
LTC1781298I2 (lt) Farmacinės kompozicijos, turinčios benzoksazino, skirtos respiracinių ligų gydymui
EA200870360A1 (ru) Бензимидазолы, обладающие активностью в отношении рецепторов м1, и их применение в медицине
NO20074615L (no) Dihydrotienopyrimidiner for behandling av inflamatoriske sykdommer
ATE476414T1 (de) Biphenyloxyessigsäurederivate zur behandlung von atemwegserkrankungen
DK1694318T3 (da) (S)-2-N-propylamino-5-hydroxytetralin som D3-agonistisk terapeutikum
NO20084328L (no) Nye forbindelser
ECSP109889A (es) Composiciones terapeuticas y usos de las mismas
NO20076695L (no) Nye MCHR1-antagonister og deres anvendelse for behandling av MCHR1-medierte tilstander og forstyrrelser
CY1111857T1 (el) Κρυσταλλικη βαση trans-1-((1r,3s)-6-xλωpo-3-φαινυλινδαν-1-υλο)-3,3-διμεθυλοπιπεραζινης
ATE539750T1 (de) Trans-4-ä2-ä4-(2,3-dichlorophenyl)-piperazin-1- ylü-ethylü-n,n-dimethylcarbamoyl-cyclohexylamin zur behandlung von schizophrenie
NO20074617L (no) Nye forbindelser for behandling av inflamotoriske sykdommer
DE602007011971D1 (de) Diaminocyclohexan- und diaminocyclopentanderivate
EA201200855A1 (ru) Модуляторы crth2
TW200640891A (en) Tartrate and malate salts of a pharmarceutical compound
EA200801629A1 (ru) Применение солей тиотропия для лечения персистирующей астмы средней тяжести

Legal Events

Date Code Title Description
CREP Change of representative

Representative=s name: PLOUGMANN & VINGTOFT, POSTBOKS 1003 SENTRUM, 0104